Nucleome Therapeutics raises oversubscribed £37.5 million Series A

Nucleome Therapeutics Limited, a biotechnology company decoding the dark matter of the human genome to discover first-in-class precision medicines, announces it has closed an oversubscribed £37.5 million Series A financing round. The funds will be used to advance the Company’s autoimmune disease programmes, fuel expansion of its dark genome atlas and further develop its pioneering platform.

Nucleome has the unique ability to discover and validate first-in-class targets through genetics, by investigating the ‘dark’ region of the human genome, which does not encode for proteins but contains 90% of disease-associated genetic changes. Understanding the role of these genetic variants has been a long-standing challenge, hindering the translation of the human genome into useful drug discovery insights.

Nucleome’s breakthrough platform combines pioneering 3D genome technology and machine learning to shed light on these variants by directly linking genes to diseases and mapping pathways with unprecedented precision for drug discovery.

“We have already made significant progress by mapping genes to genetics in a number of human immune cell types and discovering the first wave of potential first-in-class autoimmune disease targets,” said Dr Danuta Jeziorska, Chief Executive Officer and Co-founder of Nucleome Therapeutics.  “

Click here to find out more.

Recent news

Free Programme for innovators

Free Programme for innovators

Oxford Academic Health Science Network are inviting healthcare professionals in the South East to apply to join the latest cohort of free practical course supporting NHS innovators. Oxford Academic Health Science Network are looking for applications from allied health...

read more
Oxford’s first speculative ‘Lab Ready’ Building

Oxford’s first speculative ‘Lab Ready’ Building

Completion is due this summer, with availability from 15,000 sq ft up to 88,953 sq ft. Currently under construction, The Iversen Building is the first of two next generation purpose built Laboratory and Office buildings to be developed on The Oxford Science Park, with...

read more
Loading...